The Filing Desk

Whitehawk Therapeutics vs X4 Pharmaceuticals

Whitehawk Therapeutics WHWK · X4 Pharmaceuticals XFOR · Biotechnology

Whitehawk Therapeutics reported revenue of $7 million in fiscal 2025, about the same as X4 Pharmaceuticals' $6 million in fiscal 2025. Whitehawk Therapeutics' revenue fell 72.5% in its latest year, and X4 Pharmaceuticals' grew 150.0%. Whitehawk Therapeutics had an operating margin of -1601.1%, against -1336.7% at X4 Pharmaceuticals. Free cash flow was −$98 million at Whitehawk Therapeutics and −$86 million at X4 Pharmaceuticals.

Side by side

Whitehawk TherapeuticsX4 Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$7M$6M
Revenue growth−72.5%150.0%
Revenue growth a year, last 5 years−12.7%16.7%
Gross margin89.4%11.4%
Operating margin−1,601.1%−1,336.7%
Net margin−288.3%−1,218.5%
Free cash flow−$98M−$86M
Free cash flow margin−1,371.4%−1,317.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count129.0%531.0%
Last close$3.12$2.96
P/E at the last close——
Insider trades, last 12 monthssold $2.6 millionsold $428,889
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Whitehawk TherapeuticsX4 Pharmaceuticals
Operating margin
Percent of revenue
Whitehawk TherapeuticsX4 Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Whitehawk TherapeuticsX4 Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Whitehawk Therapeutics and X4 Pharmaceuticals pages.